Skip to main content

Advertisement

SpringerLink
Log in

The effect of zoledronic acid and denosumab on the mandible and other bones: a 18F-NaF-PET study

  • Original Article
  • Published:
Oral Radiology Aims and scope Submit manuscript

Abstract

Objectives

The primary purpose of this study was to determine whether both zoledronic acid (ZA) and denosumab (Dmab) equally suppress bone remodeling of the normal mandible, and the secondary purpose was to determine the influence of ZA and Dmab on other normal bones.

Methods

18F-sodium fluoride-positron-emission-tomography (18F-NaF-PET) was used to perform quantitative analysis of the bone metabolism in various parts. The end points of the study were the mean standardized uptake value (SUV) of each member of the ZA group (n = 9), the Dmab group (n = 16), and the Control group (n = 23).

Results

The SUV at the thoracic vertebrae in the ZA group were significantly lower than those of the Dmab and Control group (p < 0.05) In addition, the mean SUVs of the cervical vertebrae in the ZA group were significantly lower than those in the Control group (p < 0.05). There was no significant difference among ZA, Dmab and Control group in the other sites. There was no significant difference between the Dmab and Control groups at all sites.

Conclusions

The remodeling of mandible was not suppressed due to the treatment with anti-resorptive agents. Differences in the mechanisms of action between the BP and Dmab caused the specificity of the effect on the metabolism of normal bone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–76.

    Article  Google Scholar 

  2. Lipton A. Management of bone metastases in breast cancer. Curr Treat Options Oncol. 2005;6:161–71.

    Article  Google Scholar 

  3. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–6.

    Article  Google Scholar 

  4. O’Reilly SM, Richards MA, Rubens RD. Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer (Oxford, England: 1990). 1990;26:574–7.

    Article  Google Scholar 

  5. Wu S, Dahut WL, Gulley JL. The use of bisphosphonates in cancer patients. Acta Oncol. 2007;46:581–91.

    Article  Google Scholar 

  6. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126:13–20.

    Article  Google Scholar 

  7. Ruggiero SL, Dodson TB, Fantasia J, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg. 2014;72:1938–56.

    Article  Google Scholar 

  8. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3–23.

    Article  Google Scholar 

  9. Takahashi M, Ozaki Y, Kizawa R, et al. Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review. BMC Cancer. 2019;19:980.

    Article  Google Scholar 

  10. Limones A, Sáez-Alcaide LM, Díaz-Parreño SA, et al. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: a systematic review and meta-analysis. Med Oral Patologia Oral y Cirugia Bucal. 2020;25:e326–36.

    Google Scholar 

  11. Lockwood M, Banderudrappagari R, Suva LJ, Makhoul I. Atypical femoral fractures from bisphosphonate in cancer patients—review. J Bone Oncol. 2019;18:100259.

    Article  Google Scholar 

  12. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1–23.

    Article  Google Scholar 

  13. Gong X, Yu W, Zhao H, Su J, Sheng Q. Skeletal site-specific effects of zoledronate on in vivo bone remodeling and in vitro BMSCs Osteogenic Activity. Sci Rep. 2017;7:36129.

    Article  Google Scholar 

  14. Chang J, Hakam AE, McCauley LK. Current understanding of the pathophysiology of osteonecrosis of the jaw. Curr Osteoporos Rep. 2018;16:584–95.

    Article  Google Scholar 

  15. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332–4.

    PubMed  Google Scholar 

  16. Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR. Clinical utility of 18F-fluoride PET/CT in benign and malignant bone diseases. Bone. 2012;50:128–39.

    Article  Google Scholar 

  17. Even-Sapir E, Mishani E, Flusser G, Metser U. 18F-fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–9.

    Article  Google Scholar 

  18. Grant FD, Fahey FH, Packard AB, et al. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68–78.

    Article  Google Scholar 

  19. Langsteger W, Rezaee A, Pirich C, Beheshti M. (18)F-NaF-PET/CT and (99m)Tc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer. Semin Nucl Med. 2016;46:491–501.

    Article  Google Scholar 

  20. Ristow O, Gerngroß C, Schwaiger M, et al. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates. Br J Oral Maxillofac Surg. 2014;52:308–13.

    Article  Google Scholar 

  21. Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677–92.

    Article  Google Scholar 

  22. Plotkin LI, Bivi N, Bellido T. A bisphosphonate that does not affect osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of bone strength induced by glucocorticoids in mice. Bone. 2011;49:122–7.

    Article  Google Scholar 

  23. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150–7.

    Article  Google Scholar 

  24. Cole L, Vargo-Gogola T, Roeder R. Targeted delivery to bone and mineral deposits using bisphosphonate ligands. Adv Drug Deliv Rev. 2015;99:12.

    Article  Google Scholar 

  25. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18:75–85.

    Article  Google Scholar 

  26. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis*. Endocr Rev. 2000;21:115–37.

    PubMed  Google Scholar 

  27. Matsuura T, Mizumachi E, Katafuchi M, et al. Sex-related differences in cortical and trabecular bone quantities at the mandibular molar. J Hard Tissue Biol. 2014;23:267–74.

    Article  Google Scholar 

  28. Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging. Semin Nucl Med. 1972;2:31–7.

    Article  Google Scholar 

  29. Cook GJ, Fogelman I. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med. 2001;45:47–52.

    PubMed  Google Scholar 

  30. Bortot DC, Amorim BJ, Oki GC, et al. 18F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:1730–6.

    Article  Google Scholar 

  31. Sarikaya I, Elgazzar AH, Sarikaya A, Alfeeli M. Normal bone and soft tissue distribution of fluorine-18-sodium fluoride and artifacts on 18F-NaF PET/CT bone scan: a pictorial review. Nucl Med Commun. 2017;38:810–9.

    Article  Google Scholar 

  32. Win AZ, Aparici CM. Normal SUV values measured from NaF18- PET/CT bone scan studies. PLoS ONE. 2014;9:e108429-e.

    Article  Google Scholar 

  33. Raje N, Woo S-B, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14:2387–95.

    Article  Google Scholar 

  34. Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009;67:75–84.

    Article  Google Scholar 

  35. Wilde F, Steinhoff K, Frerich B, et al. Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2009;107:412–9.

    Article  Google Scholar 

Download references

Funding

This study did not receive any funding.

Author information

Authors and Affiliations

  1. Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan

    Mao Fushimi, Yumiko Ohbayashi, Fumi Nakai & Minoru Miyake

  2. Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan

    Takashi Norikane, Yuka Yamamoto & Yoshihiro Nishiyama

Authors
  1. Mao Fushimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yumiko Ohbayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fumi Nakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takashi Norikane
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuka Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshihiro Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Minoru Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minoru Miyake.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (the Kagawa University Ethical Committee (2020-#122)) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fushimi, M., Ohbayashi, Y., Nakai, F. et al. The effect of zoledronic acid and denosumab on the mandible and other bones: a 18F-NaF-PET study. Oral Radiol 38, 594–600 (2022). https://doi.org/10.1007/s11282-022-00594-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11282-022-00594-2

Keywords

Search

Navigation